AAIC 2023 – Lilly downplays tau testing needs
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
Big readouts ahead for small biotechs
Nash data are due for Terns and Inventiva, as Marinus aims to expand its rare disease offering.
Go or no go? Decision day looms for Eisai and Biogen
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Big biotech's upcoming clinical priorities
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
Approaching datasets for big pharma
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
ADA 2023 – Lilly unveils its triple threat
Retatrutide looks like the most powerful obesity agent yet, though side effects will need careful monitoring.
ADA 2023 – Vertex raises hopes of type 1 diabetes cure
But it still has a long way to go with its islet cell therapies.